|
End-of-day quote
Korea S.E.
02/09/2026
|
5-day change | 1st Jan Change | ||
| 5,630.00 KRW | -4.41% |
|
+6.03% | -17.45% |
| 12-09 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 12/06/25 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Main competitors
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | - | - | - | 2.05x | - | 19.98x | 102M | |
| -.--% | -.--% | -234.01x | 23.88x | 15.55x | -278.7x | -203.49x | 46.24B | |
| 0.89% | 0.9% | 23.51x | 2.96x | 2.15x | 12.15x | 14.9x | 26.57B | |
| 5.47% | 5.45% | 16.02x | 1.11x | 1.26x | 7.18x | 13.18x | 6.94B | |
| 0.97% | 1.05% | 51.51x | 11.15x | 9.49x | 32.7x | 40.6x | 3.35B | |
| -.--% | -.--% | -58.45x | - | - | - | - | 2.24B | |
| 5.25% | 6.37% | 14.5x | 2x | 1.47x | 5.77x | 9.63x | 2.03B | |
| 1.46% | 2.18% | 30.88x | 1.78x | 1.63x | 12.2x | 20.8x | 1.88B | |
| 0.84% | 1.52% | 25.62x | 1.71x | 1.05x | 8.4x | 12.22x | 1.67B | |
| 0.11% | 0.12% | 68.69x | 13.27x | 15.2x | 36.07x | 47.78x | 1.63B | |
| 3.42% | 3.44% | 41.65x | 1.49x | 0.88x | 7.44x | 25.34x | 1.26B | |
| 1.86% | 2.16% | 45.01x | 14.79x | - | - | - | 991M | |
| 0.34% | 0.41% | 28.5x | 2.14x | - | - | - | 885M | |
| 3.38% | 3.78% | 18.41x | 1.06x | - | - | - | 866M | |
| 3.96% | 4.62% | 19.23x | 1.27x | 1.47x | 6.92x | 12.14x | 624M | |
| Average | 2% | 2.29% | 6.51x | 6.05x | 4.75x | -14.99x | 1.19x | 6.48B | |
| Weighted average by Cap. | 0.94% | 1.01% | -99.31x | 13.48x | 9.22x | -133.24x | -93.04x |
- Stock Market
- Stocks
- A340450 Stock
- Sector GC Genome Corporation
- Sector dividends
Select your edition
All financial news and data tailored to specific country editions
